Abstract：Objective: To explore the safety of zoledronic acid injection in the treatment of osteoporosis and establish the method of its pharmaceutical evaluation. Methods: Clinical pharmacists participated in the treatment of one patient with osteoporosis. After review of the literature, the effectiveness and safety of zoledronic acid injection were monitored, and medication education was provided to the patient. Results: After pharmaceutical evaluation, clinical pharmacists provided treatment advices and delivered medication monitoring and education to the patient. Conclusion: For patients with osteoporosis, clinical pharmacists should provide comprehensive pharmaceutical evaluation and medication education before treatment with zoledronic acid, and pharmaceutical care should be strengthened after the initiation of treatment.
于欢,王莹,邓昂. 1例唑来膦酸注射液治疗骨质疏松的药学评估及监护[J]. 临床药物治疗杂志, 2017, 15(5): 84-87.
YU Huan, WANG Ying, DENG Ang. Pharmaceutical evaluation and care of zoledronic acid injection in the treatment of one osteoporosis patient. CLINICAL MEDICATION JOURNAL, 2017, 15(5): 84-87.
[1] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志, 2011,04(1): 2-17.
[2] Nancollas G H, Tang R, Phipps R J, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite[J].BONE, 2006, 38(5): 617-627.
[3] Black D M, Delmas P D, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J]. N Engl J Med, 2007, 356(18): 1809-1822.
[4] Gold D T, Alexander I M, Ettinger M P. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy[J].ANN PHARMACOTHER, 2006, 40(6): 1143-1150.
[5] Cosman F, de Beur S J, LeBoff M S, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis[J].Osteoporos Int, 2014, 25(10): 2359-2381.
[6] Hamdy R C. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass[J]. Drug Des Devel Ther, 2010(4): 321-335.
[7] Reid I R, Gamble G D, Mesenbrink P, et al. Characterization of and risk factors for the acute-phase response after zoledronic acid[J].J Clin Endocrinol Metab, 2010, 95(9): 4380-4387.
[8] Dalle C L, Zanatta M, Gasparetto A, et al. Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management[J].Drug Healthc Patient Saf, 2010( 2): 121-137.
[9] FDA. FDA Drug Safety Communication: New contraindication and updated warning on kidney impairment for Reclast (zoledronic acid) [EB/OL].(2011-12-06)[2016-12-19]. https://www.fda.gov/Drugs/DrugSafety/ucm270199.htm.
[10] Lee J J, Cheng S J, Wang Y P, et al. Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: report of 2 cases[J].Head Neck, 2013, 35(1): e6-e10.
[11] Black D M, Delmas P D, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J].N Engl J Med, 2007, 356(18): 1809-1822.
[12] Rosen H N. The use of bisphosphonates in postmenopausal women with osteoporosis[DB/OL].(2015-11-11)[2016-12-19]. https://www.uptodate.com/contents/the-use-of-bisphosphonates-in-postmenopausal-women-with-osteoporosis?source=Out%20of%20date%20-%20zhHans&search=%E5%94%91%E6%9D%A5%E7%A3%B7%E9%85%B8&selectedTitle=2~62.
[13] Ganz L I. Epidemiology of and risk factors for atrial fibrillation[DB/OL].(2015-03-12)[2016-12-19]. https://www.uptodate.com/contents/epidemiology-of-and-risk-factors-for-atrial-fibrillation?source=Out%20of%20date%20-%20zh-Hans.
[14] Tanvetyanon T, Stiff P J. Management of the adverse effects associated with intravenous bisphosphonates[J]. Ann Oncol, 2006, 17(6): 897-907.
[15] Tian Y, Wang R, Liu L,et al. Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report[J].BMC Musculoskelet Disord, 2016, 17(1): 72.
[16] FDA. ZOMETA (zoledronic acid) Label[DB/OL].(2016-09-12)[2016-12-19]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021223s034lbl.pdf.
2017, Vol. 15 
